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With the aim of controlling various symptoms, possible to use mixtures of different drugs within infusion 
devices. This should take into account the compatibility of the mixture. Factors influence the compatibility 
and stability of the mixtures are: drug type, concentration, solvent, temperature and light. When evaluating 
the compatibility of the mixtures for infusion for subcutaneous via is important to consider infusion 
devices used and the conditions of light and temperature should simulate as far as possible the conditions 
in practice assistance. There are diverse studies that analyze the compatibility of drug mixtures, but there 
are still many possible combinations of drugs for which evidence is not available. The objective of this 
work is to study the compatibility and stability of several mixtures of haloperidol and morphine that can 
be used in solution for subcutaneous infusion.
Keywords: Haloperidol/stability/compatibility. Morphine/stability/compatibility. Mixtures. Palliative 
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INTRODUCTION
Cancer patients who are in the terminal phase 
simultaneously suffer from various symptoms such 
as pain, nausea, anxiety, gastrointestinal obstruction 
and weakness, so that to control these symptoms, 
simultaneous administration of morphine with other 
drugs, including haloperidol, is necessary (Schrijvers 
et al., 1998).
On the other hand, many patients have great 
difficulty in taking oral medications. In these patients, 
portable infusion pumps offer the possibility of continuous 
parenteral administration of drugs while maintaining 
patient autonomy. To avoid the use of different infusion 
needles it is very useful to mix different drugs in a single 
infuser (Graham, Clark, 2005).
In the subcutaneous administration of drug 
mixtures, by means of infusors, incompatibility thereof 
or loss of stability may occur. Incompatibility may lead 
to precipitation or crystallization of the drugs leading 
to cannula blockage, skin irritation and malabsorption 
(Grassby, Hutchings, 1997).
The physical compatibility and / or stability 
of mixtures of several drugs in solution for use in 
subcutaneous infusion has been extensively studied, 
although in some studies only a visual inspection of the 
samples was performed, thus obtaining information on the 
physical compatibility but not on the chemical stability of 
the drugs in the mixture (Barcia et al., 2003; Barcia et al., 
2005; Good, Schneider, Ravenscroft, 2004; Negro et al., 
2006; Negro et al., 2007).
Morphine is an opioid analgesic used for the 
treatment of moderate to severe pain. It is recommended 
by the WHO for the relief of moderate cancer-related 
pain. It is the opioid of choice in palliative and terminal 
care. Morphine is predominantly cleared from body 
by metabolism to morphine- 3-glucuronide (M3G) 
and morphine-6-glucuronide (M6G). Haloperidol is a 
neuroleptic, conventional antipsychotic drug that is part 
of the butyrophenones.
The objective of this work is to evaluate the 
compatibility and stability of the mixtures of morphine 
and haloperidol prepared with NaCl 0.9% at different 
concentrations stored in elastomeric infusors at 25 ºC and 
37 ºC and with protection of light.
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MATERIAL AND METHODS
Chemical and reagents
Commercial morphine ampoules of 20 mg mL-1 
(Morphine, Braun, Spain) and commercial haloperidol 
ampoules of 5 mg mL-1 (Dr. Esteve Laboratory, Spain) 
were employed. Sodium chloride 0.9% was obtained from 
Fresenius Kabi, Spain. Other chemical and solvents were 
of analytical grade and obtained from Sigma-Aldrich, 
Germany. High purity water (resistivity 18.2 MΩ cm) 
obtained by a Milli-Q water purification system (Millipore, 
Bedford, MA, USA) was used throughout this work.
Drug mixtures
The doses of morphine and haloperidol assayed in 
the study were chosen taking into consideration those more 
frequently used by the units of palliative care in our region. 
The doses assayed were 0.80 mg mL-1 – 0.15 mg mL-1, 1.60 
mg mL-1 – 0.15 mg mL-1 and 3.0 mg mL-1 – 0.3 mg mL-1 
of morphine and haloperidol respectively, which were 
prepared in 0.9% normal saline for injection and stored at 
two temperatures, 25 °C and 37 ºC each one, employing 
a bacteriological and culture oven with temperature and 
time regulation and digital reading, Selecta (INCUDIGIT 
19L 2001246). Each of these six alternatives were 
prepared in triplicate in elastomeric infuser (type Travenol 
Baxter®) and protected from light. From each mixture, 
five standards of different concentrations were prepared. 
The standards were divided into different aliquot parts, 
stored in Eppendorf tubes and frozen until each analysis 
day. All the procedures were done under aseptic conditions 
and using sterile drug solutions. Each day of analysis, 
the admixtures were conveniently diluted to obtain the 
concentrations adequate for the final measurement.
Physical stability study
The physical stability of the samples was assessed 
by visual examination during all studied days for color 
change and/or precipitation.
Chemical stability study
Mixtures concentrations were determined by a 
stability-indicating HPLC method. HPLC analysis was 
performed at room temperature (~25 ºC) using a Shimadzu 
LC-6A pump equipped with Rheodine 7125 injection valve 
20 μL, a Shimadzu SPD-6A spectrophotometric detector 
working at 254 nm. The signal from the detector was 
recorder and integrated with a chromatography data system 
Shimadzu C-R6A chromatopac; a LiChrospher® 100 C18 
(5 μm) LiChroCART® 250-4 column was employed. 
The mobile phase consisted of methanol:KH2PO4 0.05 M, 
adjusted to pH 3 with H3PO3 (60:40, v/v) delivered at flow 
rate of 1.0 mL min-1. The sample injection volume was 
20 μL, and triplicate injections were performed for every 
sample. The signal was recorded during 12 minutes and 
the retention times were 2.8 for morphine and 9.8 min for 
haloperidol (Figure 1). The initial concentration of mixture 
was defined as 100%, and subsequent sample concentrations 
were expressed as a percentage of the initial concentration. 
Stability of the mixture was defined as retention of at least 
95 % of the initial mixture concentration.
Forced degradation studies 
Forced degradation study is a complementary part 
of stability testing where the influence of various stresses 
factors, such as pH, temperature, light, etc. are investigated 
(Blessy et al, 2014; Singh et al. 2013).
In this work, five different studies were carried out 
for this purpose over the mixture solution: acid, base, heat, 
UV light and hydrogen peroxide.
Compatibility and stability studies
The compatibility and stability studies were 
carried out at two different temperatures (25±0.5 ºC 
and 37±0.5 ºC), and all drug mixtures were protected 
from direct light exposure. All solutions were assayed in 
triplicate with three replicates in each case. At different 
times, the samples were examined for any development 
and/or change in color. Also, the drug mixtures were 
examined for signs of precipitation or cloudiness 
(turbidity) and gas production under bright light against 
a dark background.
FIGURE 1 - Chromatogram of the admixture morphine-
haloperidol.
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RESULTS AND DISCUSSION
Accelerated degradation study
For the performance of this accelerated degradation 
study, samples of the morphine-haloperidol mixture have 
been subjected to specific conditions to evaluate the 
physical and / or chemical changes that may occur during 
the analysis. The subsequent studies were made over 
mixture solutions containing 20 mg L-1 of morphine and 
20 mg L-1 of haloperidol.
pH study
To aliquots of 500 μL of mixture were added 
different amounts of HCl or NaOH (1 M) (100, 250 
and 500 μL). Additions of HCl have not influence 
about the chromatographic signal of haloperidol. The 
area diminishes by effect dilution when the amount of 
degradant is higher and also the signal is constant with the 
time. In the case of morphine, the signals are kept constant 
over time for a volume of 100 µL, but the influence of 1M 
HCl is observed because increasing the amount of acid 
added increases the value of the signal at the same time 
as increasing study time.
With NaOH 1 M, the haloperidol retention time is 
shifted to 10 min while the retention time of the morphine 
goes to 2.5 min. These signals decrease as the amount 
of added NaOH increases and also with the time. In 
addition, two new signals are obtained at different times 
that increase over time and the amount of NaOH added.
Heat study
Two samples of mixture solutions were heated at 
different temperatures (40 ºC and 60 ºC) during different 
times (from 5 to 60 minutes). No significant changes were 
observed in the chromatograms in all cases.
UV light
A mixture solution was subject to UV irradiation 
during several days. Retention times of haloperidol and 
morphine did not vary during the degradation study 
with ultraviolet light, however, two new signals were 
obtained at 3.5 min and 6.5 min, indicating the appearance 
of degradation products. The signal corresponding to 
haloperidol decreases as the exposure time increases, 
while the signal corresponding to the morphine remains 
constant. The signal at 3.5 min appears at 52 hours of 
exposure, while the signal at 6.5 min appears at 28 hours 
of exposure, both increase with time.
Oxidant
To aliquots of 500 μL of mixture were added different 
amounts of H2O2 3% (100, 250 and 500 μL). Additions of 
H2O2 have not influence about the chromatographic signal 
of haloperidol. The area diminishes by effect dilution 
when the amount of degradant is higher and also the 
signal is constant with the time. In the case of morphine, 
the signals increase as the added volume of the oxidizing 
agent increases, remaining constant with the study time 
for each volume.
Physical stability study
All solutions were initially clear and colorless but 
visible particles appear, in all cases, into the infusers after 
several days since their preparation. The results are shown 
in Table I.
Chemical stability study
Calibration curves were linear over the concentration 
range used with good correlation coefficients. The linearity 
of the method was evaluated at five concentration levels 
injected by triplicate. 
All  the  phys ica l ly  s t ab le  so lu t ions  were 
chromatographied. The experimental data were processed 
making use of the Statgraphics Centurion XVI program. 
The standard calibration curves exhibited good linearity 
over the range of concentrations tested, with correlation 
coefficients greater than 0.999 in all cases as can be seen 
in Table II. The percentages remaining for each mixture at 
two studied temperatures (25 ºC and 37 ºC) are shown in 
figures 2, 3 and 4. Although the admixtures were measured 
during ten days from the preparation, the figures show the 
values for the admixtures were they are considered stables 
(Table I). 
TABLE I - Physical stability study
Turbidity 
appearance
Morphine – Haloperidol (mg mL-1)
0.8 – 0.15 1.6 – 0.15 3 – 0.3
25 ºC 37 ºC 25 ºC 37 ºC 25 ºC 37 ºC
Days 9 8 4 7 3 6
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CONCLUSIONS
The administration of mixtures in palliative care 
has become increasingly popular over the last years. 
Some mixtures of drugs have proven stability, but there 
is lack of evidence about the stability and compatibility 
of the combination of haloperidol-morphine at different 
concentrations stored into infuser. After this study we 
concluded that morphine and haloperidol mixtures in 
saline solution are stable for at least three days when 
stored in an elastomeric infuser at room temperature or 
near body temperature in a concentration range of 0.15-
0.8 mg mL-1 and 0.3-3.0 mg mL-1 haloperidol-morphine 
respectively.
TABLE II - Regression equations for admixtures
Admixtures Morphine-
Haloperidol (mg mL-1) Temperature Drug Regression equation
0.8 – 0.15 25 ºC
Morphine
Slope: 3098.1 ± 23.6a 
Intercept: 2676.6 ± 1862.7a 
R2 = 0.9998
Haloperidol
Slope: 12158.3 ± 122.3a 
Intercept: -16345.0 ± 1805.4a 
R2 = 0.9997
0.8 – 0.15 37 ºC
Morphine
Slope: 2246.9 ± 40.7a 
Intercept: 13822.2 ± 3568.8a 
R2 = 0.9993
Haloperidol
Slope: 15371.0 ± 92.1a 
Intercept: -39599.1 ± 1514.5a 
R2 = 0.9999
1.6 − 0.15
25 ºC
Morphine
Slope: 2128.5 ± 32.6a 
Intercept: 20394.6 ± 5141.4a 
R2 = 0.9993
Haloperidol
Slope: 15225.4 ± 435.7a 
Intercept: -43010.0 ± 7160.2a 
R2 = 0.9990
37 ºC
Morphine
Slope: 2112.8 ± 32.3a 
Intercept: 35730.5 ± 5669.3a 
R2 = 0.9995
Haloperidol
Slope: 15118.6 ± 36.3a 
Intercept: -37417.1 ± 597.9a 
R2 = 0.9999
3 − 0.3
25 ºC
Morphine
Slope: 2203.1 ± 20.2a 
Intercept: 18861.4 ± 2571.3a 
R2 = 0.9997
Haloperidol
Slope: 16420.9 ± 324.9a 
Intercept: -39659.2 ± 4136.3a 
R2 = 0.9990
37 ºC
Morphine
Slope: 2182.0 ± 36.1a 
Intercept: 13553.8 ± 4599.9a 
R2 = 0.9992
Haloperidol
Slope: 15574.3 ± 588.5a 
Intercept: -34825.0 ± 8187.6a 
R2 = 0.9990
a Standard error for regression equation obtained by Statgraphic program
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FIGURE 2 - Percentages of mixtures remaining at 25 ºC and 37 ºC.
FIGURE 3 - Percentages of mixtures remaining at 25 ºC and 37 ºC.
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FIGURE 4 - Percentages of mixtures remaining at 25 ºC and 37 ºC.
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